SEGG Media Congratulates Lando Norris on 2025 Formula 1 World Championship

Rhea-AI Summary

IceCure Medical (Nasdaq: ICCM) presented ProSense® liquid-nitrogen single‑probe cryoablation data and training at CIRSE 2025 in Barcelona, highlighting independent clinical studies and hands‑on sessions for interventional radiologists.

Key items: PRECICE will treat 234 Luminal A/B patients >50; a prospective series reported outcomes for 55 elderly HR+/HER2- patients (median age 86); a cohort of 39 inoperable malignant lesions showed efficacy in small, low‑grade HR+ unifocal IDC; an AWE study reported pain scores falling from 8 to 1 and MRI necrosis/resolution in 95% of cases.

Positive

• PRECICE trial: 234 Luminal A/B patients enrolled using ProSense®
• Prospective study: 55 elderly HR+/HER2- patients treated with cryoablation
• AWE study: pain scores decreased from 8 to 1
• AWE MRI response: necrosis/resolution in 95% of cases
• Focused CIRSE sessions and 3 hands-on trainings increased clinician engagement

Negative

• Several clinical reports are small cohorts: 55 and 39 patients
• Primary positive findings limited to HR+ HER2- and unifocal small tumors
• PRECICE is investigator-led and sponsored externally, not a completed regulatory study

Market Context

This announcement centers on favorable clinical data and strong physician engagement around ProSense...

Analysis

This announcement centers on favorable clinical data and strong physician engagement around ProSense cryoablation, including studies in early-stage breast cancer and abdominal wall endometriosis where pain scores fell from 8 to 1 and MRI changes occurred in 95% of cases. In SEGG’s broader context, recent regulatory filings noted ongoing losses and going-concern language, so investors may monitor how such medical-technology headlines relate (if at all) to SEGG’s core media and gaming strategy.

Key Figures

Breast cancer patients: 234 patients Mean age (non-surgical cohort): 83.4 years Prospective cohort size: 55 patients +5 more

8 metrics

Breast cancer patients 234 patients PRECICE independent study using ProSense for Luminal A/B >50 years

Mean age (non-surgical cohort) 83.4 years Breast cancer patients ineligible for surgery in comparative HT/cryoablation study

Prospective cohort size 55 patients First patients treated with cryoablation at Institut Curie

Median age (Institut Curie study) 86 years Elderly patients with small HR+/HER2- breast cancers

Breast lesions assessed 39 malignant lesions Inoperable B5 lesions evaluated one year after cryoablation

Pain score reduction 8 to 1 (scale 1–10) Abdominal wall endometriosis treated with percutaneous cryoablation

MRI response rate 95% of cases AWE lesions showing necrosis and resolution of hemorrhagic signals

CIRSE meeting dates September 13–17, 2025 Conference where ProSense cryoablation data and trainings were presented

Historical Context

5 past events · Latest: Dec 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 01	Leadership change	Positive	-6.1%	Board removed prior CEO and elevated interim leadership to drive growth and discipline.
Nov 25	Platform growth update	Positive	-4.9%	Company surpassed 102 million views and reiterated expansion and acquisition plans.
Nov 20	Content acquisition	Positive	-8.2%	Agreement to acquire 51% of Ant Media & Productions and secure streaming rights.
Nov 13	Ad-tech acquisition LOI	Positive	-7.5%	Binding LOI to buy Triggy.AI to add AI-driven ad monetization capabilities.
Nov 12	Marketing expansion	Positive	-14.6%	Sports.com brand expansion via NBA yearbook advertising across major U.S. markets.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent SEGG headlines describing expansion, acquisitions, and leadership changes were followed by consistent share price declines, indicating a pattern of negative reactions to ostensibly strategic or growth-focused news.

Recent Company History

Over the past month, SEGG issued multiple growth-oriented updates, including NBA advertising expansion on Nov 12, an LOI to acquire Triggy.AI on Nov 13, and a 51% stake agreement for Ant Media & Productions on Nov 20. The company also highlighted surpassing 102 million views on Nov 25 and leadership changes on Dec 1. Despite these announcements, each event coincided with negative next-day price reactions, framing today’s decline against a backdrop of persistent skepticism.

Key Terms

cryoablation, interventional radiologists, lumpectomy, hormonal therapy, +4 more

8 terms

cryoablation medical

"developer of minimally-invasive cryoablation technology that destroys tumors by freezing"

A medical treatment that uses extreme cold to freeze and destroy unwanted tissue, such as small tumors or heart tissue causing irregular rhythms; think of it like applying a focused freezer to stop a problem spot without cutting it out. It matters to investors because devices, tools, and drugs tied to cryoablation, plus clinical results, approval status and insurance coverage, can drive sales, shape market adoption and affect the financial outlook of healthcare companies.

interventional radiologists medical

"growing number of interventional radiologists looking to grow their practice in breast care"

Interventional radiologists are doctors who use medical imaging (like X‑rays, CT scans, or ultrasound) as a live “GPS” to guide thin instruments and small needles to treat conditions without open surgery. For investors, they matter because their techniques drive demand for specialized imaging machines, disposable devices and new minimally invasive therapies, influence hospital procedure mix and reimbursement trends, and can shorten recovery times that affect healthcare costs and patient volumes.

lumpectomy medical

"from radical surgery, through lumpectomy, to current treatment alternatives"

A lumpectomy is a surgical procedure that removes a breast tumor along with a small ring of surrounding tissue, preserving most of the breast like cutting a stain out of a shirt rather than replacing the whole garment. Investors watch lumpectomy rates and related technology because they affect demand for surgical tools, hospital services, follow-up therapies and reimbursement patterns, which in turn influence revenue and cost projections for medical device makers, hospitals and insurers.

hormonal therapy medical

"cryoablation combined with hormonal therapy ("HT") versus cryoablation alone"

Hormonal therapy is a medical treatment that changes the levels or actions of hormones in the body to slow or stop disease processes, most commonly used against hormone-sensitive cancers. Investors care because clinical results, approval decisions, patent protection and market demand for these treatments can strongly affect a company’s future revenue and stock value — think of a successful hormonal therapy as unlocking a new, steady revenue stream for a drug maker.

HER2- medical

"hormone receptor-positive (HR+) human epidermal growth factor receptor 2- negative (HER2-)"

HER2- describes a tumor that lacks an excess of the HER2 protein or the gene that produces it; HER2 is a cell-surface receptor that can fuel cancer growth when overabundant. For investors, HER2- status matters because it determines whether patients will benefit from HER2-targeted medicines — like finding there is no matching lock for a specialized key — which directly affects the size of the eligible patient pool, treatment choices, pricing dynamics and potential sales for related drugs.

invasive ductal carcinoma medical

"unifocal invasive ductal carcinoma (IDC) (the patient cohort evaluated in the study)"

A common type of breast cancer that starts in the milk ducts and has grown into the surrounding breast tissue; think of it like a weed that has spread out from its original patch. It matters to investors because its prevalence, treatment options, prognosis and regulatory pathway drive demand for diagnostics, drugs, surgeries and long‑term care, which in turn affect clinical trial outcomes, healthcare spending and the commercial value of related medical companies.

percutaneous medical

"efficacy and safety of percutaneous single probe cryoablation using liquid nitrogen"

Percutaneous describes medical procedures or delivery methods that reach internal organs or tissues by passing through the skin — for example with needles, catheters or small tubes — instead of opening the body with large incisions. For investors it matters because percutaneous approaches are generally less invasive, often mean lower hospital time, quicker recovery and smaller device footprints, which can broaden market adoption and affect regulatory and reimbursement outlooks.

MRI medical

"MRI showed necrotic changes and resolution of hemorrhagic signals in 95% of cases"

Magnetic resonance imaging (MRI) is a medical scan that uses magnetic fields and radio waves to create detailed pictures of the inside of the body, like a high-resolution camera for tissues and organs. Investors care because MRI drives demand for imaging machines, hospital services, diagnostics and can be central to clinical trial results and regulatory decisions—changes in MRI use or technology can affect revenue, capital spending and reimbursement in healthcare and medical device markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FORT WORTH, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- SEGG Media Corporation (Nasdaq: SEGG, LTRYW) (“SEGG Media” or the “Company”) congratulates Lando Norris for securing his first Formula 1 World Championship in a spectacular showdown at the FORMULA 1 ETIHAD AIRWAYS ABU DHABI GRAND PRIX 2025.

This landmark achievement not only cements his place at the top of global motorsport, but also amplifies the momentum behind Quadrant, the creator-led motorsport, gaming, and apparel brand co-founded by Norris.

Through its strategic investment in Veloce Media Group and Veloce’s subsequent acquisition of Quadrant, SEGG Media is directly supporting one of the most rapidly expanding ecosystems in sport, gaming, and digital media. The investment also includes a call option for SEGG Media to acquire a 51% or higher majority stake in the future.

Quadrant’s growth has been fuelled by major partnerships with global brands including LEGO, Hilton, NordVPN, VISA, Revolut, RailsR, T-Mobile, McLaren, Microsoft, Thrustmaster, and E.ON. Norris’ World Championship win now elevates that platform to an even higher level.

Marc Bircham, Chairman of SEGG Media, said: “Lando Norris’ championship victory is an extraordinary moment for him and an accelerant for the entire Quadrant and Veloce ecosystem. Our investment strategy is built at the intersection of sports, content, gaming, and culture. Lando Norris’ success this season proves exactly why that strategy matters.”

Daniel Bailey, CEO of Veloce Media Group, said: “Lando’s World Championship win is a huge moment, and everyone at Veloce couldn’t be prouder. It’s been an unbelievable year for Quadrant too, with the brand growing faster than ever. We’ve worked closely with Lando since the very beginning and seeing both his journey and Quadrant’s success reach this level in the same season is something special.”

This week, Quadrant also launched a new apparel drop in honour of Norris’ title win. The World Championship Collection has already energised the brand’s community and reinforced Quadrant’s position as one of motorsport’s most exciting apparel players. For more details and to secure your piece of history, visit Quadrant.

As Veloce continues to scale its racing, esports, athlete-led media, and apparel operations, supported by SEGG Media’s recent investment, Norris’ world title provides a powerful tailwind for further growth.

SEGG Media looks forward to an even bigger 2026, driven by Veloce, Quadrant, and the worldwide fanbase that continues to rally behind Formula 1’s newest World Champion.

About SEGG Media Corporation
SEGG Media (Nasdaq: SEGG, LTRYW) is a global sports, entertainment and gaming group operating a portfolio of digital assets including Sports.com, Concerts.com and Lottery.com. Focused on immersive fan engagement, ethical gaming and AI-driven live experiences, SEGG Media is redefining how global audiences interact with the content they love.

Important Notice Regarding Forward-Looking Statements 

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, regarding the Company’s strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. When used in this Form 8-K, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “initiatives,” “continue,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. The forward-looking statements speak only as of the date of this press release or as of the date they are made. The Company cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. In addition, the Company cautions you that the forward-looking statements contained in this press release are subject to risks and uncertainties, including but not limited to, any future findings from ongoing review of the Company’s internal accounting controls, additional examination of the preliminary conclusions of such review, the Company’s ability to secure additional capital resources, the Company’s ability to continue as a going concern, the Company’s ability to respond in a timely and satisfactory matter to the inquiries by Nasdaq, the Company’s ability to regain compliance with the Bid Price Requirement, the Company’s ability to regain compliance with Nasdaq Listing Rules, the Company’s ability to become current with its SEC reports, and those additional risks and uncertainties discussed under the heading “Risk Factors” in the Form 10-K/A filed by the Company with the SEC on April 22, 2025, and the other documents filed, or to be filed, by the Company with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that the Company has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC’s website at www.sec.gov. Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release.

This press release was published by a CLEAR® Verified individual.

For additional information, visit www.seggmediacorp.com or contact media relations at media@seggmediacorp.com.

FAQ

What did IceCure announce about ProSense® at CIRSE 2025 (Nasdaq: ICCM)?

IceCure showcased ProSense® with 3 hands-on trainings, focused presentations, and independent studies including PRECICE (using ProSense® for 234 patients).

What were the key breast cancer study results presented for ICCM ProSense®?

Presentations reported safety and efficacy in elderly HR+/HER2- patients (55 patient prospective series) and effective control in 39 inoperable small, low‑grade IDC lesions at one year.

How did ProSense® perform in the abdominal wall endometriosis (AWE) study presented at CIRSE 2025?

The AWE study showed mean pain scores falling from 8 to 1 and MRI evidence of necrosis/resolution in 95% of cases.

What patient populations are represented in the PRECICE trial using ProSense®?

PRECICE is enrolling 234 Luminal A and B patients aged >50 with early‑stage breast cancer.

Will ProSense® broaden interventional radiology breast care based on CIRSE findings?

CIRSE presentations and trainings indicate growing clinician interest and use of ProSense® to expand interventional breast care, especially for elderly or surgery‑ineligible patients.